publication . Article . Other literature type . 2007

Model for Assessing Human Papillomavirus Vaccination Strategies

Elbasha, Elamin H.; Dasbach, Erik J.; Insinga, Ralph P.;
Open Access English
  • Published: 01 Jan 2007 Journal: Emerging Infectious Diseases (issn: 1080-6040, eissn: 1080-6059, Copyright policy)
  • Publisher: Centers for Disease Control and Prevention
Abstract
We present a transmission dynamic model that can assess the epidemiologic consequences and cost-effectiveness of alternative strategies of administering a prophylactic quadrivalent (types 6/11/16/18) human papillomavirus (HPV) vaccine in a setting of organized cervical cancer screening in the United States. Compared with current practice, vaccinating girls before the age of 12 years would reduce the incidence of genital warts (83%) and cervical cancer (78%) due to HPV 6/11/16/18. The incremental cost-effectiveness ratio (ICER) of augmenting this strategy with a temporary catch-up program for 12- to 24-year olds was US $4,666 per quality-adjusted life year (QALY)...
Subjects
Medical Subject Headings: virus diseasesfood and beveragesfungi
free text keywords: human papillomavirus, vaccines, cost-effectiveness analysis, cervical intraepithelial neoplasia, uterine cervical neoplasms, condylomata acuminate, Medicine, R, Infectious and parasitic diseases, RC109-216, Research, theoretical models, nonlinear dynamics, Genital warts, medicine.disease, Virology, Papillomavirus Vaccines, Vaccination, Cervical cancer, Herd immunity, business.industry, business
40 references, page 1 of 3

1. Baseman JG, Koutsky LA The epidemiology of human papillomavirus infections.J Clin Virol 2005;32:S16–24 10.1016/j.jcv.2004.12.008 15753008 [OpenAIRE] [PubMed] [DOI]

2. Gustafsson L, Ponten J, Zack M, Adami HO International incidence rates of invasive cervical cancer after introduction of cytological screening.Cancer Causes Control 1997;8:755–63 10.1023/A:1018435522475 9328198 [OpenAIRE] [PubMed] [DOI]

3. Parkin DM, Bray F, Ferlay J, Pisani P 2005 global cancer statistics.CA Cancer J Clin 2005;55:74–108 10.3322/canjclin.55.2.74 15761078 [OpenAIRE] [PubMed] [DOI]

4. Markowitz L, Dunne E, Gilsdorf J Development of recommendations for HPV vaccine use in the United States. Papillomavirus 22nd International Conference and Clinical Workshop 2005, Vancouver, British Columbia, Canada, Apr 30–May 6, 2005

5. Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Modeling for health care and other policy decisions: uses, roles, and validity.Value Health 2001;4:348–61 10.1046/j.1524-4733.2001.45061.x 11705125 [OpenAIRE] [PubMed] [DOI]

6. Dasbach EJ, Elbasha EH, Insinga RP Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.Epidemiol Rev 2006;28:88–100 10.1093/epirev/mxj006 16740585 [OpenAIRE] [PubMed] [DOI]

7. Edmunds WJ, Medley GF, Nokes DJ Evaluating the cost-effectiveness of vaccination programmes: a dynamic approach.Stat Med 1999;18:3263–82 10.1002/(SICI)1097-0258(19991215)18:23<3263::AID-SIM315>3.0.CO;2-3 10602150 [PubMed] [DOI]

8. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modeling analyses.PLoS Med 2006;3:e138 10.1371/journal.pmed.0030138 16573364 [OpenAIRE] [PubMed] [DOI]

9. Taira AV, Neukermans CP, Sanders GD Evaluating human papillomavirus vaccination programs.Emerg Infect Dis 2004;10:1915–23 15550200 [OpenAIRE] [PubMed]

10. Centers for Disease Control and Prevention Recommended childhood and adolescent immunization schedule—United States, 2006.Morb Mortal Wkly Rep MMWR.2006;54:Q1–4

11. Hethcote H The mathematics of infectious diseases.SIAM Rev 2000;42:599–653 10.1137/S0036144500371907 [DOI]

12. Insinga RP, Glass AG, Rush BB Pap screening in a U.S. health plan.Cancer Epidemiol Biomarkers Prev 2004;13:355–60 15006908 [PubMed]

13. Hewitt M, Devesa SS, Breen N Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey.Prev Med 2004;39:270–8 10.1016/j.ypmed.2004.03.035 15226035 [OpenAIRE] [PubMed] [DOI]

14. Schootman M, Jeffe DB, Baker EA, Walker MS Effect of area poverty rate on cancer screening across US communities.J Epidemiol Community Health 2006;60:202–7 10.1136/jech.2005.041020 16476748 [OpenAIRE] [PubMed] [DOI]

15. Bigras G, de Marval F The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women.Br J Cancer 2005;93:575–81 10.1038/sj.bjc.6602728 16136031 [OpenAIRE] [PubMed] [DOI]

40 references, page 1 of 3
Abstract
We present a transmission dynamic model that can assess the epidemiologic consequences and cost-effectiveness of alternative strategies of administering a prophylactic quadrivalent (types 6/11/16/18) human papillomavirus (HPV) vaccine in a setting of organized cervical cancer screening in the United States. Compared with current practice, vaccinating girls before the age of 12 years would reduce the incidence of genital warts (83%) and cervical cancer (78%) due to HPV 6/11/16/18. The incremental cost-effectiveness ratio (ICER) of augmenting this strategy with a temporary catch-up program for 12- to 24-year olds was US $4,666 per quality-adjusted life year (QALY)...
Subjects
Medical Subject Headings: virus diseasesfood and beveragesfungi
free text keywords: human papillomavirus, vaccines, cost-effectiveness analysis, cervical intraepithelial neoplasia, uterine cervical neoplasms, condylomata acuminate, Medicine, R, Infectious and parasitic diseases, RC109-216, Research, theoretical models, nonlinear dynamics, Genital warts, medicine.disease, Virology, Papillomavirus Vaccines, Vaccination, Cervical cancer, Herd immunity, business.industry, business
40 references, page 1 of 3

1. Baseman JG, Koutsky LA The epidemiology of human papillomavirus infections.J Clin Virol 2005;32:S16–24 10.1016/j.jcv.2004.12.008 15753008 [OpenAIRE] [PubMed] [DOI]

2. Gustafsson L, Ponten J, Zack M, Adami HO International incidence rates of invasive cervical cancer after introduction of cytological screening.Cancer Causes Control 1997;8:755–63 10.1023/A:1018435522475 9328198 [OpenAIRE] [PubMed] [DOI]

3. Parkin DM, Bray F, Ferlay J, Pisani P 2005 global cancer statistics.CA Cancer J Clin 2005;55:74–108 10.3322/canjclin.55.2.74 15761078 [OpenAIRE] [PubMed] [DOI]

4. Markowitz L, Dunne E, Gilsdorf J Development of recommendations for HPV vaccine use in the United States. Papillomavirus 22nd International Conference and Clinical Workshop 2005, Vancouver, British Columbia, Canada, Apr 30–May 6, 2005

5. Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Modeling for health care and other policy decisions: uses, roles, and validity.Value Health 2001;4:348–61 10.1046/j.1524-4733.2001.45061.x 11705125 [OpenAIRE] [PubMed] [DOI]

6. Dasbach EJ, Elbasha EH, Insinga RP Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.Epidemiol Rev 2006;28:88–100 10.1093/epirev/mxj006 16740585 [OpenAIRE] [PubMed] [DOI]

7. Edmunds WJ, Medley GF, Nokes DJ Evaluating the cost-effectiveness of vaccination programmes: a dynamic approach.Stat Med 1999;18:3263–82 10.1002/(SICI)1097-0258(19991215)18:23<3263::AID-SIM315>3.0.CO;2-3 10602150 [PubMed] [DOI]

8. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modeling analyses.PLoS Med 2006;3:e138 10.1371/journal.pmed.0030138 16573364 [OpenAIRE] [PubMed] [DOI]

9. Taira AV, Neukermans CP, Sanders GD Evaluating human papillomavirus vaccination programs.Emerg Infect Dis 2004;10:1915–23 15550200 [OpenAIRE] [PubMed]

10. Centers for Disease Control and Prevention Recommended childhood and adolescent immunization schedule—United States, 2006.Morb Mortal Wkly Rep MMWR.2006;54:Q1–4

11. Hethcote H The mathematics of infectious diseases.SIAM Rev 2000;42:599–653 10.1137/S0036144500371907 [DOI]

12. Insinga RP, Glass AG, Rush BB Pap screening in a U.S. health plan.Cancer Epidemiol Biomarkers Prev 2004;13:355–60 15006908 [PubMed]

13. Hewitt M, Devesa SS, Breen N Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey.Prev Med 2004;39:270–8 10.1016/j.ypmed.2004.03.035 15226035 [OpenAIRE] [PubMed] [DOI]

14. Schootman M, Jeffe DB, Baker EA, Walker MS Effect of area poverty rate on cancer screening across US communities.J Epidemiol Community Health 2006;60:202–7 10.1136/jech.2005.041020 16476748 [OpenAIRE] [PubMed] [DOI]

15. Bigras G, de Marval F The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women.Br J Cancer 2005;93:575–81 10.1038/sj.bjc.6602728 16136031 [OpenAIRE] [PubMed] [DOI]

40 references, page 1 of 3
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . Other literature type . 2007

Model for Assessing Human Papillomavirus Vaccination Strategies

Elbasha, Elamin H.; Dasbach, Erik J.; Insinga, Ralph P.;